

5/23/94

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	LIN ET AL.)	
SERIAL NO:	08/182,183)	
INTERNATIONAL APPLICATION NO.:	PCT/US92/07888)	EXAMINER:
INTERNATIONAL FILING DATE:	SEPTEMBER 17, 1992)	ART UNIT:
TITLE:	GLIAL DERIVED NEURO-TROPHIC FACTOR)	

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS
UNDER 35 U.S.C. 371 IN THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)


Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231
Box PCT

Dear Sir:

This document and its attachment is submitted in response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) dated May 4, 1994.

1) In response to item 2, a fully executed Combined Declaration for Patent Application and Power of Attorney is submitted.

Respectfully submitted,


Barry J. Swanson
Registration No. 33,215
Beaton & Swanson, P.C.
4582 S. Ulster St. Parkway
Suite 403
Denver, CO 80237
Telephone: (303) 850-9900

37 CFR 1.8
CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

May 13, 1994.

Signature: _____

Name: Barry J. Swanson

synergen\225\correct.doc /tec



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Of
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Box PCT
Washington, D.C. 20514

#2

08-182183

US APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
08/182,183	LIN	L SYNE225/C4-U

INTERNATIONAL APPLICATION NO.

PCT/US92/07888

LA. FILING DATE

PRIORITY DATE

09/17/92

09/20/91

DATE MAILED: 05/04/94

5611
BARRY J. SWANSON
BEATON & SWANSON, P.C.
4582 S. ULSTER ST. PARKWAY, SUITE 403
DENVER, COLORADO 80237

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as

- ☐ a Designated Office (37 CFR 1.494),
☒ an Elected Office (37 CFR 1.495):

☒ U.S. Basic National Fee.

☒ Copy of the international application in:

☐ a non-English language.

☒ English.

☐ Translation of the international application into English.

☐ Oath or Declaration of inventors(s) for DO/EO/US.

☐ Copy of Article 19 amendments.

☐ Translation of Article 19 amendments into English.

☒ The International Preliminary Examination Report in English and its Annexes, if any.

☐ Translation of Annexes to the International Preliminary Examination Report into English.

☐ Preliminary amendment(s) filed _____ and _____.

☐ Information Disclosure Statement(s) filed _____ and _____.

☐ Assignment document.

☐ Power of Attorney and /or Change of Address.

☐ Substitute specification filed _____.

☐ Verified Statement Claiming Small Entity Status.

☐ Priority Document

☐ Other:

2. The following items **MUST** be furnished within the time period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- ☐ a. Translation of the application into English. Note a processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.

☐ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.

- ☐ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).

☒ c. Oath or Declaration of the inventors, in compliance with 37 CFR 1.63, identifying the application by International application number and international filing date.

☐ The current oath or declaration does not comply with 37 CFR 1.63 for the reasons indicated on the attached PTO-152.

☒ d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).

3. Additional claim fees of \$ _____ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due. See attached PTO-875.

ALL OF THE ITEMS SET FORTH IN 2(a) -2(d) AND 3 ABOVE MUST BE SUBMITTED WITHIN ONE MONTH FROM THE DATE OF THIS NOTICE OR BY ☐ 21 or ☐ 31 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

4. Translation of the Annexes **MUST** be submitted no later than the time period set above or the annexes will be cancelled. Note a processing fee will be required if submitted later than 30 months from the priority date.

5. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5).

A copy of this notice MUST be returned with the response.

Enclosed: ☐ PTO-152 ☐ Notice of Defective Translation
☐ PTO-875

FORM PCT/DO/EO/905 (May 1993)

Edmund M. Reed
Telephone: (703) 305-3165



BEATON & SWANSON, P.C.
4582 S. Ulster St. Pkwy.
#403
Denver, CO 80237

Date: May 13, 1994
Applicant: Lin et al.
Serial No.: 08/182,183
For: Glial Derived Neurotrophic Factor

RECEIPT IS HEREBY ACKNOWLEDGED OF: Response to Notification
of Missing Requirements Under 35 U.S.C. 371 in the United
States Designated/Elected Office (DO/EO/US); Combined
Declaration for Patent Application and Power of Attorney; and
copy of Notice.

BEST AVAILABLE COPY